DNA Script is a Paris-based biotechnology company that has developed a breakthrough enzymatic DNA synthesis platform. Unlike traditional chemical DNA synthesis methods, DNA Script uses proprietary enzymes to write DNA sequences, enabling faster, more sustainable, and higher-quality synthetic DNA production. The company's technology has applications in genomics research, personalized medicine, and biotechnology manufacturing. DNA Script has raised significant funding and partnered with major pharmaceutical and biotechnology companies to commercialize its platform, representing a potentially transformative approach to synthetic biology.
DNA Script has received investment from 1 venture capital firm.
Biotechnology company developing enzymatic DNA synthesis technology to enable on-demand, decentralized production of synthetic DNA for research and therapeutics.
DNA Script has received investment from Kurma Partners. These venture capital firms and investors provide both capital and strategic support.
DNA Script has raised $134M in total funding, with their most recent round being a Series B. The company operates in the Biotech sector.
DNA Script was founded in 2014 and is headquartered in Paris, France.
DNA Script operates in the Biotech sector. Biotechnology company developing enzymatic DNA synthesis technology to enable on-demand, decentralized production of synthetic DNA for research and therapeutics.
